QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:MNMD

Mind Medicine (MindMed) (MNMD) Stock Forecast, Price & News

$3.62
+0.03 (+0.84%)
(As of 09/26/2023 ET)
Compare
Today's Range
$3.54
$3.76
50-Day Range
$3.59
$4.93
52-Week Range
$2.12
$6.23
Volume
422,717 shs
Average Volume
513,648 shs
Market Capitalization
$143.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.67

Mind Medicine (MindMed) MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
526.2% Upside
$22.67 Price Target
Short Interest
Healthy
12.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of Mind Medicine (MindMed) in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$278,196 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($2.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

446th out of 964 stocks

Medicinals & Botanicals Industry

4th out of 11 stocks


MNMD stock logo

About Mind Medicine (MindMed) (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company working to develop therapies and treatments based on psychoactive substances. The company develops novel products including psychoactive substances and digital medicine to treat brain health disorders related to psychiatry, addiction, pain, and neurology. Digital medicine is the use of technology to measure and intervene in the service of human health and is a budding industry of its own. The company has 10 compounds in pre-clinical or clinical trials and 4 are on track to advance to Phase 1. The company is headquartered in Vancouver, Canada.

Mind Medicine’s pipeline of drug candidates is based on emerging science that more than suggests psychoactive substances can be used to relieve stress and anxiety disorders in the brain. Among the many potential uses for these drugs is the treatment of anxiety and stress related to PTSD and secondary stress disorders related to the treatment of people suffering from stress and anxiety-related disorders. Psychoactive compounds have also been shown to be effective in treating autism, pain, and social disorders.

The company’s treatments are focused on neuroplasticity or the fact our brain function is tied to its structure and the structure of our brains can change over time. When used in the proper context, Mind Medicine’s treatments aid the restructuring of brain activity and how it organizes information by catalyzing plasticity. In some cases, patients under treatment learn to make positive associations in relation to stress-inducing stimuli while under the influence of the treatments.

In addition to plasticity, psychoactive drugs like LSD, psilocybin, and DMT have been shown to have experiential effects such as lowering mental barriers and reducing defensive and often reflexive mechanisms that can be an impediment to healing.

Among the benefits of using psychoactive compounds versus traditional therapeutics are the speed of efficacy and greatly reduced side effects. Psychoactive drugs can produce positive effects in patients with the first use while it may take weeks for the current treatments to take effect and they come with many side effects. In some cases, side effects of mainstream treatments include an increase in suicidal behavior.

The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain. MM-120 is LSD D-tartrate. MM-110 is a nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Mind Medicine also develops MM-402 which is for the treatment of core symptoms of autism spectrum disorder. This treatment is based on MDMA and improves sociability in autistic patients without stimulants and is shown to have superior safety and tolerability.

 

MNMD Price History

MNMD Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 1%
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
The Latest Analyst Ratings for Mind Medicine
See More Headlines
Receive MNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.

MNMD Company Calendar

Last Earnings
8/03/2023
Today
9/26/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNMD
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.67
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+512.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-56,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
38,879,000
Market Cap
$146.96 million
Optionable
Not Optionable
Beta
2.17
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Robert Barrow (Age 34)
    CEO & Director
    Comp: $956.1k
  • Mr. Schond L. Greenway M.B.A. (Age 51)
    Chief Financial Officer
    Comp: $343.28k
  • Dr. Daniel Rollings Karlin M.A. (Age 42)
    M.D., Chief Medical Officer
    Comp: $663.63k
  • Dr. Miriam Halperin Wernli Ph.D. (Age 70)
    Exec. Pres
  • Dr. Scott M. Freeman M.D. (Age 66)
    Co-Founder & Clinical Advisor
  • Mr. Leonard Latchman
    Co-founder
  • Ms. Carrie F. Liao CPA
    CGMA, VP & Chief Accounting Officer
  • Mr. Maxim Jacobs C.F.A.
    VP of Investor Relations & Corp. Communications
  • Mr. Mark R. Sullivan J.D. (Age 52)
    Chief Legal Officer & Corp. Sec.
  • Dr. Francois P. Lilienthal M.B.A.
    M.D., Chief Commercial Officer













MNMD Stock - Frequently Asked Questions

Should I buy or sell Mind Medicine (MindMed) stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNMD shares.
View MNMD analyst ratings
or view top-rated stocks.

What is Mind Medicine (MindMed)'s stock price forecast for 2023?

8 equities research analysts have issued 12-month price objectives for Mind Medicine (MindMed)'s shares. Their MNMD share price forecasts range from $7.00 to $75.00. On average, they predict the company's share price to reach $22.67 in the next twelve months. This suggests a possible upside of 512.6% from the stock's current price.
View analysts price targets for MNMD
or view top-rated stocks among Wall Street analysts.

How have MNMD shares performed in 2023?

Mind Medicine (MindMed)'s stock was trading at $2.20 on January 1st, 2023. Since then, MNMD shares have increased by 68.2% and is now trading at $3.70.
View the best growth stocks for 2023 here
.

When is Mind Medicine (MindMed)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MNMD earnings forecast
.

How were Mind Medicine (MindMed)'s earnings last quarter?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by $0.18.

What ETF holds Mind Medicine (MindMed)'s stock ?

AdvisorShares Psychedelics ETF holds 123,228 shares of MNMD stock, representing 7.16% of its portfolio.

When did Mind Medicine (MindMed)'s stock split?

Mind Medicine (MindMed)'s stock reverse split on the morning of Monday, August 29th 2022. The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Mind Medicine (MindMed)'s stock symbol?

Mind Medicine (MindMed) trades on the NASDAQ under the ticker symbol "MNMD."

Who are Mind Medicine (MindMed)'s major shareholders?

Mind Medicine (MindMed)'s stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.43%), Geode Capital Management LLC (0.96%), Bank of New York Mellon Corp (0.17%), Northern Trust Corp (0.16%), Citadel Advisors LLC (0.00%) and Renaissance Technologies LLC (0.09%). Insiders that own company stock include Dan Karlin, Robert Barrow and Schond L Greenway.
View institutional ownership trends
.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mind Medicine (MindMed)'s stock price today?

One share of MNMD stock can currently be purchased for approximately $3.70.

How much money does Mind Medicine (MindMed) make?

Mind Medicine (MindMed) (NASDAQ:MNMD) has a market capitalization of $146.96 million. The company earns $-56,800,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

How can I contact Mind Medicine (MindMed)?

The official website for the company is www.mindmed.co. The company can be reached via phone at 650-208-2454 or via email at ir@mindmed.co.

This page (NASDAQ:MNMD) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -